UPDATE: Hank Blalock signs minor league deal with Rays

0 Comments

UPDATE: Blalock has agreed to a minor league contract with the Rays, according to Jon Heyman of SI.com. He’ll receive a $925,000 base salary if he makes the team plus $350,000 in performance incentives.
Monday 11:58am: MLB.com’s Bill Chastain reports that “the Rays appear to be close to signing Hank Blalock to a minor-league deal.” And manager Joe Maddon all but confirmed the move when asked this morning, saying: “I anticipate that it’s going to get done relatively soon.”
Blalock smacked 25 homers in 462 at-bats last season, but hit a career-worst .234 with a putrid .277 on-base percentage and 108/26 K/BB ratio in the process, missed most of 2007 and 2008 with injuries, and may not be able to play third base any longer thanks to shoulder problems. In other words, a minor-league pact sounds about right.
He’ll likely compete with Pat Burrell for playing time at designated hitter, with a strict lefty-righty platoon being an option. Blalock reportedly also had a similar offer from the Marlins, but the Rays probably represent a better chance for significant action as well as a better team.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
0 Comments

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.